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7 Abstract
8 Large-scale, low-cost genome analysis has become possible with next-generation sequencing technology, which is currently
9 used in research and clinical practice. Many attempts of returning individual genomic results have commenced not only in
10 clinical practice, but also in research settings of several countries. In Japan, the government guidelines include a section on
11 the disclosure of genetic information regarding genome analysis in research. However, no practical guidance for the return of
12 individual genomic results in research settings (ROGRR) currently exists. We propose practical guidance regarding ROGRR
13 in Japan based on extensive research, including a literature review of related previous studies, an examination of the relevant
14 legislation in Japan, and interviews with stakeholders. The guidance we developed consists of “Points to consider” and
15 “Issues for further discussion and consideration.” The “Points to consider” were divided into five parts, from preliminary
16 review before discussion of policy, to the actual return and follow-up process, in the order of the assumed ROGRR process.
17 It is anticipated that a situation will arise where numerous research projects will consider ROGRR carefully and realistically
18 in the future, and in the process of drafting such practical guidance, various issues requiring continuous discussion will
19 emerge. The necessities of continuous discussion concerning ROGRR in Japan’s context is increasing, particularly in terms
20 of the ethical, legal, and social implications. We believe such discussions and considerations may contribute to creating a
21 new system that will increase availability of personalized medicine and prevention using genetic information, allowing them
22 to become useful to the broader population.
23 Introduction
24 Large-scale, low-cost genome analysisQ1 has become possible
25 with next-generation sequencing technology, which is cur-
26 rently used in research and clinical practice. In 2013, the
27 American College of Medical Genetics and Genomics pub-
28 lished policy statements on the return of incidental findings
29 (subsequently revised as “secondary findings”) in clinical
30exome and genome sequencing [1, 2], which prompted
31widespread and diverse discussion [3–5]. There is also
32growing debate about returning genomic research results to
33participants [6–8]. Numerous attempts to return individual
34genomic results have been initiated not only in clinical but
35also in research settings in several countries [9–12]. Q2
36In Japan, the government’s Ethical Guidelines for
37Human Genome/Gene Analysis Research (JEGHG)
38includes a section on the Disclosure of Genetic Information
39regarding genome analysis in research, which states, “With
40regard to human genome/gene analysis research through
Q341which the genetic information of individual donors is
42obtained, when a donor has requested disclosure of that, the
43researchers shall, in principle, disclose the requested infor-
44mation.” [13] This description reflects the importance of
Q445participants' right to know their own information, which
46may have great impact on the participants' health. Yet, there
47is little mention of specific points to consider [13]. Although
48Japanese academic society guidelines on clinical genetic
49testing have been presented [14], no practical guidance on
50the return of individual genomic results in research settings
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51 (ROGRR) exists. Nevertheless, with the increase of data
52 and knowledge on disease-causing variants, it is likely that
53 researchers will need guidance to effectively deal with
54 them. We posit that practical guidance tailored to the cur-
55 rent state of affairs in Japan is needed for researchers
56 handling ROGRR. Therefore, this study aims to propose the
57 first Japanese practical guidance for ROGRR based on
58 extensive research.
59 Methods
60 To understand the current circumstances affiliated with
61 ROGRR, several investigations were conducted, including a
62 literature review of previous studies on ROGRR, an
63 examination of the relevant legislation in Japan, and inter-
64 views with stakeholders. Fifteen researchers and genomics
65 experts were interviewed. In some interviews, interviewees’
66 collaborators participated, increasing the total number of
67 interviewees to 20. The researchers interviewed were the
68 principal investigators of the ten themes of the Japan
69 Agency for Medical Research and the Development funded
70 Platform Program for Promotion of Genome Medicine
71 Advanced Genome R&D, which was selected as the main
72 target for large-scale projects on human genome analysis.
73 The five experts other than the researchers were selected
74 purposively for their wide range of knowledge of the issues
75 around ROGRR, including medical geneticists, an expert of
76 clinical laboratory, and an individual with a genetic condi-
77 tion. All interviews were recorded and with the permission
78 of the interviewees, summaries were subsequently created
79 and classified as points of interest. Based on these results,
80 we prepared drafts of the practical guidance for ROGRR for
81 stakeholders in Japan that consist of “Points to consider”
82 and “Issues for further discussion and consideration,”
83 respectively. The drafts of the guidance were also reviewed
84 by the five supervisors of the Japan Agency for Medical
85 Research and the Development’s research project men-
86 tioned above. Feedback was requested from 20 groups
87 including the interviewees. The final version of the gui-
88 dance and the summery of the investigations described
89 above were published on the Japan Agency for Medical
90 Research and the Development website in Japanese [15].Q5
91 In this paper, we present “Points to consider” as sug-
92 gestions that provide practical guidance in the “Results”
93 section, while the “Discussion” section was composed
94 based on “Issues for future discussion and consideration,”
95 as well as other content deemed relevant. Before each
96 interview, we asked interviewees about recording and
97 summarizing an interview for making drafts of the practical
98 guidance, and verbal consent was obtained. Following the
99 completion of this guidance, written informed consent (IC)
100 regarding publishing was obtained from all interviewees.
101This study was approved by the Institutional Review Boards
102of Tohoku Medical Megabank Organization at Tohoku
103University (2019-4-004) and Osaka University (19041).
104Results
105Preliminary investigations
106Literature review of previous studies on ROGRR
107A total of 27 published research articles met the criteria and
10822 projects were mentioned in those articles (Supplemen-
109tary Table 1). There were 13 projects in the US, one each in
110the UK, Canada, Sweden, Estonia, Singapore, Germany,
111Australia, Switzerland, and Japan. Three projects returned
112results in medical research including the use of samples and
113information in biobanks. Five projects included research
114participants who were ostensibly healthy people. Eleven
115projects returned secondary findings in studies regarding
116rare diseases or cancer, and three projects were considering
117ROGRR in the future.
118Examination of the relevant legislation in Japan
119We investigated Japanese legislations related to the
120ROGRR. Major legislation governing the return (dis-
121closure) of genomic results include the Act on the Protec-
122tion of Personal Information and the related laws, JEGHG,
123Ethical Guidelines for Medical and Health Research
124Involving Human Subjects, among others (see Table 1).
125Under the Act on the Protection of Personal Information,
126personal information (including genomic information)
127should be disclosed if the concerned person requested, but
128this principle is exempted for research use. The use is
129regulated by research guidelines, such as JEGHG.
130Research that analyzes germline variants requires
131adherence to the JEGHG, and it is based on the principle of
132disclosure if the concerned person requested, but nondi-
133sclosure is permitted in certain cases.
134Interviews with stakeholders
135All contacted persons participated in an interview. Inter-
136views were conducted either at their office or in a public
137meeting room, and lasted 30–90 min. All researchers were
138engaged with human genome analysis research, and had
139various backgrounds, including physicians, molecular or
140informatics biologists, or researchers belonging to institutes
141not affiliated with medical institutions. Some researchers
142responded that their project planned to or did ROGRR, and
143the rest commented that their project could not ROGRR for
144some reasons. Some experts had experiences of ROGRR as










145 researchers. Interview summaries classified as points of
146 interest are shown in Table 2, and the detailed results were
147 published as a report on the website [15].
148 Points to consider: return of individual genomic
149 results in research settings
150 Introduction of “points to consider”
151 Several “Points to consider” were proposed for the practical
152 guidance for ROGRR. Researchers determine the overall
153 policy on ROGRR and proceed with the return process after
154 a thorough investigation, which accounts for the char-
155 acteristics of the genetic information. It is necessary to
156 proceed according to the specific characteristics for each
157 research project.
158 In a determination of the ROGRR policy of each project,
159 it is required to observe the JEGHG and other relevant
160 legislation and guidelines. Moreover, when implementing a
161 return plan, the institutional review board of the relevant
162 facility should be consulted and provide approval for said
163 plan prior to its implementation.
164 This guidance does not recommend actively imple-
165 menting ROGRR in every research project. However, as
166 there may be possibly important findings related to the
167 health and reproduction of research participants in the
168 information obtained in research based on genomic analy-
169 sis, we hoped that attempts of ROGRR in various situations
170 will increase. Hopefully, this guidance will serve as a useful
171reference for the numerous situations that projects may need
172to consider ROGRR.
173Scope of guidance
174The return of germline genetic information is the primary
175target within ROGRR based on the description in the
176JEGEG. In addition to the return of primary findings (e.g.,
177results concerning rare genetic diseases for patients), which
178has been carried out for a few decades, this section is
179concerned with the following possible situations in which
180ROGRR would occur: the return of relevant variant infor-
181mation in cases where intervention research (e.g., clinical
182trials) is conducted using the results of genome analysis, the
183return of genetic information aimed at evaluating the return
184process and psychosocial facts, and the return of secondary
185findings and incidental findings. New situations could
186emerge in the future, including the return of risk informa-
187tion on multifactorial diseases and returnable secondary
188findings from transcriptome/epigenome analysis. Moreover,
189given that the context of performing whole genome/exome
190analysis in research differs from clinical genetic testing, it
191was assumed that there would be situations where it would
192be difficult to clearly classify returnable genetic information
193into primary, secondary, and incidental findings. Therefore,
194comprehensive references will be provided in this guidance
195without classifying genetic information to return. Further-
196more, although it is described as the “disclosure” of genetic
197information in JEGHG, we will use the term “return” in this
Table 1 Scope of applications and targets of major laws and guidelines
Name Established year Latest
revision
Major scope of applications and targets
Act on the Protection of Personal Information 2003 2019 Private business operator handling personal information
Act on the Protection of Personal Information Held
by Administrative Organs
2003 2019 State administrative organs
Act on the Protection of Personal Information Held
by Incorporated Administrative Agencies
2003 2019 Incorporated administrative agencies
Ordinances for the Protection of Personal Information
Held by Local Governments
– – Local governments
Fundamental Principles of Research on the Human
Genome (Council for Science and Technology,
Bioethics Committee)
2000 – Research on human genome
Ethical Guidelines for Human Genome/Gene Analysis
Research (MEXT, MHLW, METI)
2001 2017 Human genome/gene analysis research
Ethical Guidelines for Medical and Health Research
Involving Human Subjects (MEXT, MHLW)
2014 2017 Medical and health research involving human subjects
which is carried out by a Japanese research institution or
carried out in Japan
Guidelines for clinical research of gene
therapy (MHLW)
2002 2019 Clinical research of gene therapya
MEXT Ministry of Education, Culture, Sports, Science and Technology, MHLW Ministry of Health, Labour and Welfare, METI Ministry of
Economy, Trade and Industry
aThese guidelines were newly established after substantial revision of the previous guidelines which were first enforced by MEXT and MHLW
in 2002










198 guidance, as it is assumed that the variants related to the
199 target genetic information have been detected and research
200 participants will be informed of the results based on expert
201 interpretation, genetic counseling, and adequate follow-up,
202 including referrals to medical professionals.
203 Characteristics of germline genetic information
204 Depending on the type of information returned, ROGRR
205 could lead to the genetic testing and diagnosis of research
206 participants and their respective biological relatives.
207 Therefore, it is necessary to consider the characteristics of
208 genetic information just as carefully as genetic testing and
209 diagnosis in clinical practice.
210 Points to consider on ROGRR
211 We assume that ROGRR consists of the following process:
212 preliminary review before discussion of policy on ROGRR,
213 discussion and determination of policy on ROGRR (a
214 nonreturn policy is a possible option at this stage), IC and
215 confirmation of preference for ROGRR, analysis related to
216 information with possibility of return, and return of results
217 to research participants who prefer the genetic information.
218 Several pertinent points are listed below. Researchers ought
219 to give due consideration to the circumstantial variation of
220 each project (e.g., difficulty designing a plan in detail before
221 the onset of research and limited participant contact during
222 and after the study), while considering when and how to
223 examine the following points.
224 Preliminary review before discussion of policy on ROGRR
225 When planning research, because the situations around
226 ROGRR related to genetic information differ depending on
227the research purpose and content, it is advisable to review
228points (1) through (6) before designing the plan in detail
229regarding policy on ROGRR. A summary of this section is
230shown in Fig. 1.
231(1) In interventional and observational research based on
232genetic information, it may be necessary to return the
233relevant genetic information to research participants.
234Confirm whether the return of the results is included
235in the main research purpose and content as in, for
236example, interventional research using the results of
237genome analysis to determine the administration of
238medication, or the return of genetic information to
239evaluate psychosocial factors or verify the return
240process. In applicable cases, proceed to (6), and
241consider the specific return details and methods in
242accordance with the purpose and content of the
243research, as well as points required by associated laws
244and guidelines.
245(2) For research other than what was covered in (1),
246confirm whether the samples and information used for
247analysis are newly acquired in the research or based
248on the use of preexisting samples and information
249through the transfer of samples and information or
250cooperative research. Plans in place to acquire new
251samples and information should proceed to (4).
252(3) Research on preexisting samples and information
253ought to carefully consider whether ROGRR is
254possible by checking the original terms of use and
255contractual content (with the supplier) in the transfer
256of samples and information or any cooperative
257research and the accompanying consent with respect
258to the possibility of ROGRR. It should also consider
259whether it is possible to reconnect genomic analysis
260results with individual information (e.g., contact
Table 2 Classified points of
interest based on interviews
summary
Main theme Sub theme
1. Overview of research projects and current status of ROGRR
2. Experiences and opinions about ROGRR
(1) Determination of policy
on ROGRR
(1) Research purpose and content
(2) Systems and background on determination of policy
(3) Research participants, numbers, situation eligible for ROGRR
(4) Types of genetic information planned to return
(5) IC and confirmation of preference for ROGRR
(6) Actual methods and systems on ROGRR
(7) Cost and human resources
(8) Response for requests to disclosures
(2) Analysis related to information
with possibility of return
(1) Quality control (2) interpretation (3) reidentification (4)
confirmation testing
(3) ROGRR to research participants (1) Results report (2) retaining records related to ROGRR (3)
information to explain (4) follow-up
(4) Issues to be addressed by all
stakeholders
(1) Establishing guidelines (2) coordinating among stakeholders
(3) progress of medical research and healthcare (4) data sharing










261 details), and whether it is possible to recontact
262 research participants regarding ROGRR.
263 (4) New research based on the acquisition of original
264 samples and information or the use of preexisting data
265 where ROGRR may be possible should consider
266 whether returnable genetic information can be
267 obtained. At this point, if genome-wide analysis
268 (e.g., whole genome/exome analysis) is planned,
269 researchers should expect possible ROGRR and
270 examine the feasibility of actual return, regardless of
271 whether the research planned to detect variants out of
272 the research purpose.
273 (5) If returnable genetic information is expected to be
274 obtained in (3), it is important to consider whether
275 such research can feasibly secure the necessary
276 financial and human resources for ROGRR, including
277 analysis expenses, which may include confirmation
278 testing, and a system that can provide genetic
279 counseling.
280 (6) After considering points (1) through (5), review the
281 points presented in JEGHG policy concerned with
282 determining whether genetic information is accurate
283 and reliable enough to assess donor’s health
284condition, which indicate important facts related to
285his or her health, and whether such disclosure could
286disrupt the appropriate research procedures.
287
288Discussion and decision of policy on ROGRR
289(1) Framework for the consideration and decision of policy
290on ROGRR:
291● Discuss the policy on ROGRR among researchers on the
292project, including researchers from cooperative research
293institutions, and in the case of using preexisting samples
294and information, the supplier of them.
295● It is desirable to reference the opinions of diverse
296stakeholders, including potential eligible research parti-
297cipants and the researchers involved, when discussing
298policy. For large-scale projects and the expected return
299of various genetic information, consider, when neces-
300sary, requesting the assistance of external experts during
301the policy discussion stage.
302● When deciding policy that does not plan to ROGRR, as
303a result of the aforementioned considerations, ensure
Fig. 1 Return of Individual Genomic Information in Research Settings (ROGRR): Flowchart for preliminary review before discussion on policy










304 that the policy is in line with the JEGHG. This will
305 include providing a clear explanation of why the results
306 will not be returned on the IC form.
307 ● The ROGRR policy should be approved by an
308 Institutional Review Board.
309
310 (2) Points to consider for detailed discussion
311 on ROGRR:
312 ● Persons eligible for ROGRR:
313 ● It is important to keep in mind that some features of
314 ROGRR differ from clinical situations that provide
315 healthcare with genetic testing included. These
316 features include the fact that research participants
317 may not develop the specific disease being as
318 research target (ROGRR may include unexpected
319 findings for research participants), considerable time
320 may elapse between providing IC and ROGRR,
321 opportunities to make contact with researchers are
322 limited, and it may be difficult to collect informa-
323 tion, such as medical history and family history, in
324 advance.
325 ● When research participants are obviously biologi-
326 cally related in Trio analysis and etcetera, give due
327 consideration of the return process and heed
328 particular attention to participants’ “right not to
329 know” among those that do not wish for ROGRR.
330 This may entail providing an appropriate explana-
331 tion of the nature of genetic information sharing
332 among relatives while IC intentions are confirmed
333 for ROGRR.
334 ● If research participants pass away by the time the
335 ROGRR is ready, please carefully consider whether
336 to return the results to the family of the deceased
337 (biological relatives), while taking account of the
338 characteristics of the genetic information being
339 returned. If a policy allows ROGRR to family of
340 the deceased (biological relatives), it is important to
341 carefully consider aspects of the return process,
342 including whether the deceased participant wishes
343 the information to be returned to his/her family of
344 the deceased (biological relatives) after death, and
345 which family of the deceased (biological relatives)
346 will receive the information.
347 ● If proxy consent is needed for research participants
348 who, for example, has dementia or who is a minor,
349 carefully consider policy following the JEGHG.
350
351 ● Types of genetic information planned to return:
352 ● Examine what kind of genetic information can be
353 returned. Candidates for ROGRR include primary
354findings (discovered in the research process) and
355secondary findings (entailing the targeted detection
356of variants). Carefully consider the accuracy and
357reliability of the candidate genetic information.
358When planning to return the information with
359uncertainty about accuracy or reliability necessarily,
360researchers should be mindful of the possible
361misunderstanding or psychological stress that may
362emerge in research participants.
363● Carefully consider whether the candidate genetic
364information returned may lead to carrier status or
365presymptomatic testing in participants and whether
366such information should be included for return. In
367the case that it is included, cautiously consider
368planning a return process that accommodates the
369potential medical and psychological impact on
370participants.
371● Carefully assess the potential impact that returning
372candidate genetic information could have on
373research participants post return and responses that
374could be anticipated based on the information at
375hand. In particular, when anticipating the return of
376pathogenic variants related to monogenic diseases
377(including multifactorial diseases with a clear
378involvement of specific genes), collect and evaluate
379any information related to the analytical validity,
380clinical validity, and clinical utility of the diseases. It
381is also highly recommended that physicians with
382extensive medical experience with the disease and
383experienced genetic counselors are involved in any
384deliberation and a system that allows the procure-
385ment of advice in advance is established. Specific
386points are illustrated in the subsequent paragraphs.
387● Consider whether the analytical validity of the
388candidate genetic information can be confirmed. It
389is important to verify whether there are available
390laboratories for confirmation testing as a clinical
391testing laboratory, because this process is also
392relevant to situations where genetic testing of
393biological relatives is conducted after ROGRR.
394● It is important to consider the method of variant
395interpretation and kind of variants to be returned
396when assessing the clinical validity of the candidate
397genetic information. It also particularly important to
398consider the variant interpretation process when
399information regarding the phenotype of research
400participants is limited; for example, in population-
401based research or when there are potential non/
402presymptomatic participants present.
403● When evaluating the clinical utility of the candidate
404genetic information, carefully consider, in addition
405to medical care following the return (e.g., treatment
406and prevention), whether medical care for the










407 disease is provided in the healthcare system
408 (including descriptions of medical practice guide-
409 lines) and the accessibility of medical institutions to
410 participants. It is particularly important to carefully
411 consider whether follow-up is available with/without
412 public insurance post return, in which there is a
413 possibility of returning the candidate genetic infor-
414 mation to presymptomatic participants.
415
416 ● Ensuring systems to facilitate ROGRR as a research
417 project:
418 ● The systems required for ROGRR vary depending
419 on the scale of the research, the genetic information
420 to be returned, and its disease frequency. Consider
421 whether it is possible to ensure that there will be
422 systems in place that respond appropriately to
423 inquiries from research participants during the
424 ROGRR process, including whether the researchers
425 themselves will respond and/or the provision of
426 opportunities for genetic counseling. When neces-
427 sary, ensure a system that provides access to
428 professional support for genetic counseling, includ-
429 ing clinical geneticists and certified genetic
430 counselors.
431 ● As research participants may need medical care after
432 ROGRR, especially in the case of research con-
433 ducted at institutes not affiliated with medical
434 institutions and research that targets healthy people
435 and the general population, it is desirable to consider
436 in advance which medical institutions participants
437 could be referred to.
438 ● Consider in advance who will pay for the expenses
439 related to medical care after ROGRR, such as
440 genetic counseling, confirmation testing, and
441 responses to biological relatives, while bearing in
442 mind that expenses may be high.
443 ● Please consider beforehand the response for requests
444 to disclosures related to genetic information that the
445 project was not expected to return.
446
447 IC and confirmation of preference for ROGRR
448 ● For the IC process of the research, consider what kind of
449 information will be communicated concerning ROGRR,
450 including the content detailed in the IC documents. Take
451 full account of the fact that confirming the preference for
452 the return of specific genetic information may later lead
453 to the delivery of unexpected information to research
454 participants. Reflect on a return process that is conscious
455 of the potential psychological impact, especially when
456 detailed information is not provided on the genetic
457information expected in the ROGRR during IC. More-
458over, give full consideration to the fact that time may
459pass from the point of IC to ROGRR, as stated
460previously.
461● Consider the content of the IC documents including the
462differences from clinical testing, the expected period
463until the return, and the fact that there are various
464limitations on ROGRR. In particular, when the patients
465participate in research at a medical institution, pay close
466attention to the possibility that the participants may
467perceive ROGRR as clinical testing.
468● The opportunities to confirm the intentions of research
469participants for ROGRR vary depending on the project.
470Fully reflect on the fact that it will be possible to confirm
471intentions for ROGRR in more detail.
472● It is important to adopt more careful methods of
473identification when obtaining IC and confirming of the
474intentions for ROGRR. Consider what method will be
475used to confirm identity beforehand depending on the
476method of communication with research participants
477(e.g., face-to-face, telephone, or written communication).
478● When confirming intentions for ROGRR, it is important
479to ensure research participants of their “right not to
480know.” However, carefully consider the content and
481methods used to allow research participants to make an
482informed choice based on their full understanding,
483particularly when genetic information being potentially
484returned has extremely high clinical utility and failure to
485inform such information would be life-threatening.
486
487Analysis related to information with possibility of return
488(1) Quality control and confirmation testing:
489● Depending on the research, the intended findings vary,
490including specific variants of individuals and statistical
491trends in groups, and so the quality of analysis required
492varies accordingly. Consider the methods of quality
493control during analysis in conjunction with the con-
494firmation testing described below (based on the research
495purpose and content).
496● Carefully consider the method and timing of confirma-
497tion testing beforehand, particularly when it is expected
498that results being returned may or will be used in clinical
499settings, including the recollection of samples and
500reanalysis of them at a clinical laboratory using a
501quality assurance system designed for clinical genetic
502testing; full consideration should be given to the risks,
503such as limits on the accuracy of the analytic methods,
504sample mix-ups due to de-identification, and human
505error. It is desirable to consider such things in advance,
506in conjunction with the system used for providing










507 genetic testing when biological relatives request testing
508 following ROGRR.
509
510 2) Process for variant interpretation
511
512 ● Implement the process of identifying candidate variants
513 and interpreting their significance after carefully con-
514 sidering the specific procedure and system selected
515 beforehand, including the use of reference databases and
516 convening expert panels for interpretation.
517 ● When returning results in situations characterized by
518 limited opportunities to collect information on the
519 phenotypes of the research participants beforehand, for
520 example, in research that targets the general population
521 and the return of secondary findings, careful considera-
522 tion may be needed regarding the collection of
523 information on clinical symptoms and family history
524 and the use of reassessment by experts.
525 ● Even when outsourcing analysis, including variant
526 interpretation, to an external institution, such as a
527 registered clinical laboratory, results should be returned
528 only after fully considering and reinterpreting the results
529 by research project.
530 ● Consider the possibility of reanalysis and reinterpreta-
531 tion after ROGRR based on the information to be
532 returned and the research purpose and content. In
533 addition, when results are returned to participants,
534 please ensure an opportunity to provide an explanation
535 alongside a discussion of the limitations of such testing.
536
537 Return of results to research participants who prefer to
538 receive the genetic information
539 (1) Process of ROGRR:
540 ● When the preparations for returning genetic information
541 are ready, reconfirm the intent of the research partici-
542 pants. In situations that did not provide detailed
543 candidate genetic information beforehand, fully consider
544 the procedure that may be involved in recontacting
545 research participants to ensure their “right not to know.”
546 At this point, it is also desirable to consider the response
547 policy given to research participants that do not request
548 return or request postponing ROGRR beforehand.9
550 ● Confirm the understanding and memory of research
551 participants and explain essential concepts again, as
552 necessary, before ROGRR because the research partici-
553 pants will not recall details on ROGRR due to factors
554 like the passage of time since their enrollment in
555 research.
556● When ROGRR, fully consider the fact that it may be
557difficult to collect information that causes ROGRR
558related psychological stress, such as social situations,
559including life events and the health condition of research
560participants; this is particularly pertinent for research in
561nonmedical institutions. For research that conducts
562genome-wide analysis, fully consider the possibility
563that unexpected results may be returned to research
564participants. Furthermore, please ensure that the research
565participants are informed in advance by including a
566description in IC documents that details the possibility
567of social disadvantage, such as genetic discrimination
568for ROGRR because of the lack of legal prohibition of
569genetic discrimination in Japan.
570● Reflect on the return procedure that will be used (e.g.,
571face-to-face, telephone, or written communication) as
572well as the explanatory content that will be included,
573depending on the type of genetic information and the
574particular circumstances of research participants. Sub-
575stantively consider their privacy and the possibility of
576inducing psychological stress. In particular, it is
577desirable that the genetic information that indicates the
578risk of developing disease (e.g., monogenic diseases) is
579returned face-to-face in a place where privacy is
580ensured. When returning information related to health,
581please ensure the involvement of professionals, such as
582clinical geneticists, certified genetic counselors, and
583experts on the particular disease for the point of
584ROGRR, and implement the process of making genetic
585counseling available when necessary.
586● Explain the characteristics of returning of research
587analysis results, that is not equivalent to clinical testing,
588as well as their limitations in comprehensible terms for
589research participants. Depending on the circumstances,
590also inform research participants that ROGRR and
591genetic testing related to such information is an
592advanced or innovative approach at present. In parti-
593cular, when returning a negative genetic result of a
594disease, carefully explain the need to continue with
595healthy behavior, such as going for a health checkup and
596medical treatment, rather than ignoring or dismissing the
597possibility of a high risk of developing a disease.
598● Even when ROGRR is employed face-to-face and by
599phone, it is desirable that documents that include the
600results and explanatory matters written in an under-
601standable form are delivered to the research participants.
602Consider the possibility that other family members will
603also receive the results from the same project and
604prepare the report with his or her name on it, so the
605relevant participants will know that which report is
606their own.
607










608 (2) Records related to ROGRR:
609
610 It is desirable to retain records related to ROGRR
611 including subsequent referrals to medical institutions for a
612 certain period while anticipating being contacted by
613 research participants. In addition, consider the method of
614 record keeping within the research project in advance and
615 have taken measures to prevent any leakage of information.
616 (3) Follow-up:
617 ● When referring research participants to medical institu-
618 tions, carefully provide an explanation of the specific
619 details related to visiting a medical institution, including
620 the expected procedures and approximate expenses for
621 the research participant involved, after sharing sufficient
622 information with the medical institution in the referral
623 beforehand.
624 ● Keep in mind that not all research participants that
625 receive results will be continuously engaged with a
626 medical institution, particularly when negative genetic
627 results (such as no detection of significant genetic
628 variants) are also included in the scope of the return. For
629 most of the projects, though the research duration is
630 limited, and it is desirable to provide a helpline to
631 respond to contacts from research participants for a
632 certain period after ROGRR. Also, reflect on the




637 We proposed the first Japanese practical guidance for
638 ROGRR. In Japan, there are few reports that have imple-
639 mented ROGRR, particularly in large-scale genome
640 research [16, 17], and it is anticipated in the future that
641 many research projects will consider ROGRR carefully and
642 realistically. To our knowledge, there are few cases such as
643 our collaborative work with various experts regarding
644 genomic research and healthcare and researchers specialized
645 in ethical, legal, and social implications. In addition, in the
646 process of drafting the practical guidance above described,
647 we found various issues that require continuous discussion
648 and engagement. Those that are particularly important are
649 listed below.
650 First, it is fundamentally important to pursue continuous
651 efforts related to enhancing genomic medicine delivery
652 systems. Japan’s healthcare system is characterized by
653 access to advanced medical care at a low cost to patients
654 owing to the universal insurance system that provides all
655 citizens with public health insurance [18]. However,
656 insurance often does not cover treatment options such as
657genetic testing, genetic counseling, and medical care;
658especially in surveillance and preventive treatments of
659presymptomatic individuals. For example, only 79 diseases
660are currently covered by insurance in Japan, while pre-
661ventive management of hereditary breast and ovarian cancer
662syndrome, such as risk-reducing salpingo-oophorectomy
663and risk-reducing mastectomy, are only available at limited
664medical institutions and are not covered by insurance. The
665results of interviews with stakeholders suggested that this
666situation could represent an obstacle that may hamper the
667current positive perceptions of ROGRR carried out by
668researchers. It is important that personalized treatment and
669prevention based on genetic information be evaluated from
670multiple perspectives (e.g., medical economics or patient
671advocacy). Continued discussion on the medical care
672delivery system, including public insurance coverage,
673should be encouraged. It is necessary to direct existing
674efforts to develop systems that cater for large number of
675people who require genomic medicine and can provide
676access to appropriate treatment and prevention, beyond the
677issues related to ROGRR.
678The second issue is the need to provide ROGRR support
679systems for researchers. In the research that ROGRR is not
680included in the original protocol, researchers have to make
681extra efforts when putting ROGRR into practice. Especially
682if the research is conducted by nonmedical professional
683researchers or institutes without any related hospital, there
684may be more difficulties on ROGRR. In particular, when
685genetic information outside of the researchers’ expertise is
686selected as the target for the return, the process of inter-
687preting pathogenic variants that require accuracy and
688reliability as well as referral to a clinical specialist, is a
689burden for researchers. If there will be actionable genetic
690information that is frequently returned, it is necessary to
691consider what efforts can be carried out to reduce the bur-
692den on researchers, including outsourcing processes related
693to the detection and determination of pathogenic variants,
694the creation of tailored results reports for entities external to
695the research project [19], and the use of medical institu-
696tional networks involved in genomic medicine.
697The third pertinent issue is the expense associated with
698ROGRR. When implementing ROGRR, it is necessary to
699secure the expense budget required to conduct confirmation
700testing, recontact research participants, and return their
701results, especially in the case of secondary use of stored
702samples and information. However, in our interviews of
703researchers, some of them stated that it is difficult to figure
704out whether it is possible to include expenses related to
705ROGRR into their budget, particularly in the research where
706ROGRR is not included in the original protocol. Much
707research that accompanies large-scale genome analysis in
708Japan is conducted using grants predominantly funded by
709government agencies. We consider the guidance provided










710 by said funding agencies regarding ROGRR and distinct
711 policy on its implementation in the budget would help
712 researchers that think ROGRR is possible within their fra-
713 mework and technology.
714 In preparing this practical guidance, we conducted
715 interviews with Japanese stakeholders, collected compre-
716 hensive information in Japan and overseas by conducing
717 literature reviews, and attempted to propose a practical
718 guidance that aligns with the current state of affairs in
719 Japan. However, there are some limitations. We could not
720 collect enough previous cases with ROGRR because we
721 searched only published articles. The interviews had a small
722 sample size with election method bias. Moreover, we
723 compiled the guidance with a focus on the points to con-
724 sider from the perspectives concerned with the ethical,
725 legal, and social implications of ROGRR, and we could not
726 treat some specific details, such as proxy consent and
727 nonreturn policy. In the future, it is hoped that consideration
728 regarding the practical guidelines on such matters like
729 quality control will be advanced through expert-centered
730 discussions. Under the current government’s JEGHG, in
731 principle, researchers requested to keep genetic information
732 as de-identified data, and there is no description on how to
733 manage such information for ROGRR. Given the possibility
734 that genetic information returned is used in clinical practice
735 and shared with biological relatives, we think that research
736 projects have to respond to the inquiries from research
737 participants at least for a while. On the other hand, it may
738 raise another concern about protecting such personal
739 information. We think that stored genetic information in a
740 relinked state with personal information should be kept to a
741 limited. We should discuss how we should store such
742 information for ROGRR especially when it is conducted on
743 a large scale.
744 It is necessary to continuously discuss the problems
745 related to ROGRR in the context of Japan’s genomic
746 research and medicine practices, particularly regarding
747 ethical, legal, and social implications. Moreover, we believe
748 these discussions and considerations by various stake-
749 holders, including research participants, researchers, and
750 national government agencies, can contribute to creating a
751 new system that will allow personalized medicine and
752 prevention using genetic information to become more
753 familiar and useful to the general population.
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